Shares of Li Auto Inc. LI fell sharply in today's pre-market trading after the company reported fourth-quarter results. Li ...

Steward Partners Investment Advisory LLC boosted its position in CorMedix Inc. (NASDAQ:CRMD – Free Report) by 2.2% during the ...

D. Boral Capital restated their buy rating on shares of CorMedix (NASDAQ:CRMD – Free Report) in a report released on ...

Fintel reports that on March 7, 2025, Leerink Partners initiated coverage of CorMedix (NasdaqGM:CRMD) with a Outperform ...

Leerink analyst Roanna Ruiz initiated coverage of CorMedix (CRMD) with an Outperform rating and $18 price target The firm believes the ...

This biopharma company firmly exited the penny stock status in the second half of 2024. Now priced at $9.95, CorMedix (NASDAQ:CRMD) stock is up 200% over the year. Elliott Investment has a stake at ...

BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...

DefenCath, CorMedix's primary product, has been at the center of the company's recent success. The product, designed for use in outpatient settings, has shown promising signs since its launch. The ...

DefenCath, CorMedix's primary product, has been at the center of the company's recent success. The product, designed for use in outpatient settings, has shown promising signs since its launch.